NCT03796377View on ClinicalTrials.gov

Rivaroxaban Hypericum Trial

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

February 13, 2019

Primary Completion Date

April 9, 2019

Study Completion Date

April 9, 2019

Conditions

Drug Interaction Study

Interventions

DRUG

St Johns Wort Extract

20 mg rivaroxaban after supplementation with St. John's wort extract (Jarsin®) twice daily 450 mg po for 2 weeks.

DRUG

Rivaroxaban

20 mg rivaroxaban.

Trial Locations (1)

Unknown

Inselspital, Bern

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Insel Gruppe AG, University Hospital Bern

OTHER

NCT03796377 - Rivaroxaban Hypericum Trial | Biotech Hunter | Biotech Hunter